Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises. 2 Stocks to Add to Your Watchlist The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information. With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The final step today is to look at a stock that meets our ESP qualifications. Novartis (NVS) earns a Zacks Rank #2 13 days from its next quarterly earnings release on October 29, 2024, and its Most Accurate Estimate comes in at $1.97 a share. By taking the percentage difference between the $1.97 Most Accurate Estimate and the $1.94 Zacks Consensus Estimate, Novartis has an Earnings ESP of 1.65%. NVS is just one of a large group of Medical stocks with a positive ESP figure. HCA Healthcare (HCA) is another qualifying stock you may want to consider. HCA Healthcare, which is readying to report earnings on October 25, 2024, sits at a Zacks Rank #2 (Buy) right now. It's Most Accurate Estimate is currently $5.15 a share, and HCA is nine days out from its next earnings report. The Zacks Consensus Estimate for HCA Healthcare is $4.97, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of 3.67%. NVS and HCA's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. Find Stocks to Buy or Sell Before They're Reported Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS):Free Stock Analysis Report HCA Healthcare, Inc. (HCA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...